Sydney, Australia, 08 November 2019: Recce Pharmaceuticals Ltd (ASX: RCE) (Recce or the Company), developing a new class of synthetic antibiotics, today released its presentation at the World Anti-Microbial Resistance Congress in Washington D.C., 7-8 November 2019.
Picture: Chairman Dr Prendergast
Dr John Prendergast, Chairman of Recce Pharmaceuticals, today delivered the Opening R&D Address on “How synthetic antibiotic development can change the antibiotic treatment model”. Supporting slides available here. The Company has further been invited to Lead a Panel at the Economist Anti-Microbial Resistance Summit Asia Thursday 5 December 2019 in Singapore and looks forward to updating in due course.
Dr Prendergast’s talk will be available in the coming weeks on the company’s website.
Issued for and on behalf of Recce by Instinctif Partners.
For more information please contact: Recce@instinctif.com